Untargeted metabolic analysis in dried blood spots reveals metabolic signature in 22q11.2 deletion syndrome

D. Korteling, M.P. Boks*, A.M. Fiksinski, I.N. van Hoek, J.A.S. Vorstman, N.M. Verhoeven-Duif, J.J.M. Jans, J.R. Zinkstok*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The 22q11.2 deletion syndrome (22q11.2DS) is characterized by a well-defined microdeletion and is associated with increased risk of neurodevelopmental phenotypes including autism spectrum disorders (ASD) and intellectual impairment. The typically deleted region in 22q11.2DS contains multiple genes with the potential of altering metabolism. Deficits in metabolic processes during early brain development may help explain the increased prevalence of neurodevelopmental phenotypes seen in 22q11.2DS. However, relatively little is known about the metabolic impact of the 22q11.2 deletion, while such insight may lead to increased understanding of the etiology. We performed untargeted metabolic analysis in a large sample of dried blood spots derived from 49 22q11.2DS patients and 87 controls, to identify a metabolic signature for 22q11.2DS. We also examined trait-specific metabolomic patterns within 22q11.2DS patients, focusing on intelligence (intelligence quotient, IQ) and ASD. We used the Boruta algorithm to select metabolites distinguishing patients from controls, patients with ASD from patients without, and patients with an IQ score in the lowest range from patients with an IQ score in the highest range. The relevance of the selected metabolites was visualized with principal component score plots, after which random forest analysis and logistic regression were used to measure predictive performance of the selected metabolites. Analysis yielded a distinct metabolic signature for 22q11.2DS as compared to controls, and trait-specific (IQ and ASD) metabolomic patterns within 22q11.2DS patients. The metabolic characteristics of 22q11.2DS provide insights in biological mechanisms underlying the neurodevelopmental phenotype and may ultimately aid in identifying novel therapeutic targets for patients with developmental disorders.
Original languageEnglish
Article number97
Number of pages7
JournalTranslational Psychiatry
Volume12
Issue number1
DOIs
Publication statusPublished - 9 Mar 2022

Keywords

  • DISORDERS
  • CHILDREN
  • HYPERPROLINEMIA
  • BRAIN
  • RISK

Cite this